News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing: 1–36
Matches: 228
Sources here: 11
Companies here: 4

Search results Stored financial headlines Latest headline 17:00, 19 August 2026

Active search

228 matching headlines

Ticker or company: MRKMain company stories

Clear

Latest17:00 · 19 August 2026

finance.yahoo.com Earnings

Eli Lilly, Novo Nordisk and Merck: Buy, Sell or Hold?

Quick Read LLY dominates the GLP-1 race with 48% revenue growth and an unpriced Retratrutide catalyst, while NVO battles 50% Wegovy price cuts and pipeline setbacks. Merck has rallied 31% year to date and now trades near its analyst mean target, making the next leg dependent on 2027 pipeline catalysts. Act now: the analyst who called NVIDIA in …

Main company 🇺🇸 United States

Read at finance.yahoo.com

Sharemaestro market context Trend signal active 52 weeks +60.7%

Just inNext headlines

16:41 19 Aug 2026

finance.yahoo.com Market update Main company 🇺🇸 United States

Moderna & Merck stocks skyrocket on their cancer vaccine trial's success. Here's what to know.

Wall Street Horizon head of corporate event research Christine Short and Sherwood News markets editor Luke Kawa chat with Yahoo Finance's Julie Hyman about Moderna's (MRNA) and Merck's (MRK) melanoma vaccine trial success. Video Transcript 00:00 Speaker A Moderna and Merck that they had …

MRK main company

Sharemaestro market context Trend signal active 52 weeks +60.7%

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

15:36 19 Aug 2026

finance.yahoo.com Earnings Main company 🇺🇸 United States

Moderna Skyrockets 150%, Merck Jumps On Late-Stage Cancer Vaccine Trial Win

Moderna skyrocketed and Merck jumped on strong late-stage trial results for their cancer vaccine in melanoma patients Wednesday. Continue Reading

MRK main company

Sharemaestro market context Trend signal active 52 weeks +60.7%

15:22 19 Aug 2026

Reuters Earnings Main company 🇺🇸 United States

Moderna-Merck melanoma vaccine data boosts outlook, but analysts await full results: Instant View

Moderna and Merck's personalized mRNA cancer therapy has shown significant improvement in reducing melanoma recurrence and spread when combined with Keytruda in a late-stage trial. This positive interim data sent Moderna's shares soaring and has boosted confidence in mRNA-based cancer therapies, according to analysts. …

MRK main company

Sharemaestro market context Trend signal active 52 weeks +60.7%

15:08 19 Aug 2026

finance.yahoo.com Earnings Main company 🇺🇸 United States

Merck (MRK) Posts First Successful Phase 3 Individualized mRNA Cancer Vaccine Result

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Merck (NYSE:MRK) and Moderna report positive Phase 3 results for their individualized mRNA-based melanoma vaccine in combination with KEYTRUDA. The trial is the first successful …

MRK main company

Sharemaestro market context Trend signal active 52 weeks +60.7%

14:47 19 Aug 2026

TradingKey Earnings Main company 🇺🇸 United States

Merck & Co Inc Stock (MRK) Opened Up by 8.82% on Aug 19: Key Drivers Unveiled

Merck & Co Inc (MRK) stock opened up by 8.82% due to positive Phase 3 results from its INTerpath-001 trial with Moderna, validating their individualized mRNA-based cancer vaccine combined with Keytruda. This clinical breakthrough addresses concerns about Keytruda's patent loss, strengthens Merck's oncology leadership, …

MRK main company

Sharemaestro market context Trend signal active 52 weeks +60.7%

14:39 19 Aug 2026

The Cryptonomist Earnings Main company 🇺🇸 United States

Merck & Company, Inc. stock Analysis: Daily Trend & Vaccine Impact

Merck & Company, Inc. (MRK) stock shows a split between a strong daily bullish trend and cooling short-term momentum, trading at $135.17. The daily chart indicates continued upside potential, reinforced by positive news from its melanoma vaccine trial with Moderna which met primary endpoints. …

MRK main company

Sharemaestro market context Trend signal active 52 weeks +60.7%

14:22 19 Aug 2026

finance.yahoo.com Analyst action Main company 🇺🇸 United States

Moderna Rockets 93%, Merck Jumps 7% as Melanoma Therapy Meets Primary Goal in Phase 3 Trial

Quick Read Moderna surges 93% and Merck gains 7% after their cancer combo becomes the first personalized mRNA therapy to clear a Phase 3 trial. BioNTech, the other major mRNA cancer developer, rose just 1% while the broad XLV ETF gained only 2% as …

MRK main company

Sharemaestro market context Trend signal active 52 weeks +60.7%

14:19 19 Aug 2026

finance.yahoo.com Macro sensitivity Main company 🇺🇸 United States

Moderna, Merck, SK Hynix, Micron, Target, Estée Lauder, and More Stocks That Explain Today’s Market

Stocks were rising Wednesday as investors awaited minutes from the Federal Open Market Committee’s most recent monetary policy meeting. Moderna surged 88% and Merck advanced 6.7% after the two companies said a customized vaccine kept patients cancer-free for longer than standard treatments after melanoma …

MRK main company

Sharemaestro market context Trend signal active 52 weeks +60.7%

13:10 19 Aug 2026

finance.yahoo.com Earnings Main company 🇺🇸 United States

Moderna Skyrockets 90%, Merck Jumps On Late-Stage Cancer Vaccine Trial Win

Moderna skyrocketed and Merck jumped on strong late-stage trial results for their cancer vaccine in melanoma patients Wednesday. Continue Reading

MRK main company

Sharemaestro market context Trend signal active 52 weeks +60.7%

13:08 19 Aug 2026

StocksToTrade Earnings Main company 🇺🇸 United States

Merck Stock Climbs As Analysts Hike Price Targets And Pipeline Delivers

Merck & Company Inc. stock (MRK) has climbed 7.4% due to positive drug trial results and analyst price target hikes. Several major firms, including Daiwa and JPMorgan, have raised their price targets for MRK, citing strong pipeline performance and regulatory approvals for key drugs …

MRK main company

Sharemaestro market context Trend signal active 52 weeks +60.7%

12:35 19 Aug 2026

finance.yahoo.com Earnings Main company 🇺🇸 United States

Moderna Skyrockets Over 60%, Merck Jumps On Late-Stage Cancer Vaccine Trial Win

Moderna skyrocketed and Merck jumped on strong late-stage trial results for their cancer vaccine in melanoma patients Wednesday. Continue Reading

MRK main company

Sharemaestro market context Trend signal active 52 weeks +60.7%

12:35 19 Aug 2026

finance.yahoo.com Macro sensitivity Main company 🇦🇷 Argentina

Moderna, Merck, La-Z-Boy, SK Hynix, and More Stocks That Explain Today’s Market

Stock markets are waited on minutes of the Fed's most recent monetary policy meeting for any clues about the forward path on interest rates. Continue Reading

MRK main company MRK main company MRK main company MRK main company

Sharemaestro market context Trend signal active 52 weeks +83.6%

12:33 19 Aug 2026

Quartz Earnings Main company 🇺🇸 United States

Moderna and Merck personalized melanoma vaccine passes Phase 3 trial

Moderna and Merck announced that their personalized mRNA-based cancer vaccine, combined with Merck's Keytruda, met its primary and secondary endpoints in a Phase 3 trial for high-risk melanoma patients. This marks the first positive Phase 3 result for an individualized neoantigen therapy and an …

MRK main company

Sharemaestro market context Trend signal active 52 weeks +60.7%

12:09 19 Aug 2026

finance.yahoo.com Market update Main company 🇦🇷 Argentina

Moderna Stock Surges 60%, Merck Rises 6%. At Last, a Successful Cancer Vaccine.

A successful cancer vaccine would be an important new market for Moderna, whose investors have been impatient for it to expand beyond its Covid prevention vaccine. Continue Reading

MRK main company MRK main company MRK main company MRK main company

Sharemaestro market context Trend signal active 52 weeks +83.6%

11:49 19 Aug 2026

Reuters Earnings Main company 🇺🇸 United States

Merck, Moderna say melanoma skin cancer vaccine meets goals in large trial

Merck and Moderna announced positive late-stage trial results for their personalized mRNA vaccine combined with Keytruda, showing it reduced skin cancer recurrence and spread compared to Keytruda alone. This marks the first positive late-stage trial for an mRNA cancer vaccine. The treatment, called Intismeran, …

MRK main company

Sharemaestro market context Trend signal active 52 weeks +60.7%

11:45 19 Aug 2026

finance.yahoo.com Market update Main company 🇺🇸 United States

Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma

First and only combination regimen to demonstrate statistically significant and clinically meaningful improvements in RFS and DMFS compared to KEYTRUDA alone for these patients in the adjuvant melanoma setting The Companies plan to present data at an upcoming international medical meeting and will engage …

MRK main company

Sharemaestro market context Trend signal active 52 weeks +60.7%

11:44 19 Aug 2026

WSJ Market update Main company 🇺🇸 United States

Moderna, Merck Vaccine Succeeds in Preventing Melanoma From Returning

An experimental mRNA-based vaccine developed by Moderna and Merck has shown success in preventing the recurrence or spread of melanoma in high-risk patients. This marks a significant step forward for mRNA-based therapeutic cancer vaccines and could offer a new life-extending treatment for those diagnosed …

MRK main company

Sharemaestro market context Trend signal active 52 weeks +60.7%

10:27 19 Aug 2026

MarketBeat Earnings Main company 🇺🇸 United States

Merck & Co., Inc. $MRK Shares Purchased by Vest Financial LLC

Vest Financial LLC increased its stake in Merck & Co., Inc. by 13.7% in the second quarter, bringing its total holdings to 85,329 shares valued at approximately $11.0 million. Institutional investors collectively own 76.07% of MRK, and analysts maintain a "Moderate Buy" rating with …

MRK main company

Sharemaestro market context Trend signal active 52 weeks +60.7%

08:31 19 Aug 2026

MarketBeat Earnings Main company 🇺🇸 United States

Merck & Co., Inc. (NYSE:MRK) Sets New 12-Month High - Here's What Happened

Merck & Co., Inc. (NYSE:MRK) stock reached a new 52-week high of $137.98 during trading on Wednesday, closing at $135.3360. The company recently reported its earnings, beating analyst estimates, and announced a quarterly dividend of $0.85 per share. Several analysts have upgraded their price …

MRK main company

Sharemaestro market context Trend signal active 52 weeks +60.7%

19:16 18 Aug 2026

finance.yahoo.com Guidance Main company 🇺🇸 United States

Should Merck’s (MRK) Higher 2026 Sales Outlook and New Drug Approvals Require Action From Investors?

In early August 2026, Merck reported second-quarter sales of US$16,607 million and a net loss of US$1,335 million, raised its 2026 sales outlook, and advanced its pipeline with ENFLONSIA label expansion filings for high-risk young children and a new KEYTRUDA combination approval for muscle-invasive …

MRK main company

Sharemaestro market context Trend signal active 52 weeks +60.7%

13:14 18 Aug 2026

Benzinga Earnings Main company 🇺🇸 United States

Cisco, Merck, Cheniere Energy And More: CNBC’s ‘Final Trades’

During CNBC's "Halftime Report Final Trades," experts shared their top stock picks. Stephen Weiss recommended Cisco Systems, citing strong quarterly earnings that surpassed analyst estimates. Jim Lebenthal picked Cheniere Energy, which recently received a raised price target from TD Cowen. Shannon Saccocia suggested the …

MRK main company

Sharemaestro market context Trend signal active 52 weeks +60.7%

12:00 18 Aug 2026

MarketBeat Deals and strategy Main company 🇺🇸 United States

Merck & Co. Inc. Invests $9.04 Billion in Sutro Biopharma, Inc. $STRO

Merck & Co. Inc. has acquired a new stake of 272,351 shares in Sutro Biopharma, Inc., valued at approximately $9.04 billion, representing 1.64

MRK main company

Sharemaestro market context Trend signal active 52 weeks +60.7%

11:45 18 Aug 2026

MarketBeat Earnings Main company 🇺🇸 United States

Merck & Co. Inc. Takes Position in Kymera Therapeutics, Inc. $KYMR

Merck & Co. Inc. has acquired a significant position in Kymera Therapeutics, Inc., purchasing 772,165 shares valued at over $88 billion and making it their third-largest portfolio holding. Despite substantial insider selling from Kymera's CFO and CEO in recent months, analysts maintain a "Moderate …

MRK main company

Sharemaestro market context Trend signal active 52 weeks +60.7%

10:38 18 Aug 2026

Kalkine Media Deals and strategy Main company 🇺🇸 United States

What Is Driving Interest in Merck & Co. (NYSE:MRK) as Pharmaceutical Deals Keep Flowing?

Merck & Co. (NYSE:MRK) is drawing investor attention due to sustained pharmaceutical deal activity, strong performance from major drugmakers, and recent vaccine approvals within the healthcare sector. The company's diverse portfolio, encompassing oncology, vaccines, and animal health, positions it well amidst industry trends like …

MRK main company

Sharemaestro market context Trend signal active 52 weeks +60.7%

10:16 18 Aug 2026

MarketBeat Earnings Main company 🇺🇸 United States

Munich Reinsurance Co Stock Corp in Munich Grows Stake in Merck & Co., Inc. $MRK

Munich Reinsurance Co Stock Corp in Munich significantly increased its stake in Merck & Co., Inc. (NYSE:MRK) by 37.9% in the second quarter, bringing its total holdings to 1.04 million shares valued at $133.4 million. This move positions Merck as the fourth-largest holding in …

MRK main company

Sharemaestro market context Trend signal active 52 weeks +60.7%

10:16 18 Aug 2026

MarketBeat Analyst action Main company 🇺🇸 United States

Mizuho Markets Cayman LP Invests $960,000 in Merck & Co., Inc. $MRK

Mizuho Markets Cayman LP recently invested approximately $960,000 in Merck & Co., Inc. by acquiring 7,473 shares during the second quarter. This move is part of broader institutional interest, with hedge funds owning 76.07% of MRK. Analysts maintain a "Moderate Buy" rating for Merck, …

MRK main company

Sharemaestro market context Trend signal active 52 weeks +60.7%

07:10 18 Aug 2026

finance.yahoo.com Earnings Main company 🇺🇸 United States

Merck KGaA (XTRA:MRK) Stock May Be Below Fair Value Despite Fresh Drug Pipeline Funding

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Merck KGaA's share price has recovered over the past year, yet long term holders …

MRK main company

Sharemaestro market context Trend signal active 52 weeks +60.7%

09:54 17 Aug 2026

MarketBeat Analyst action Main company 🇺🇸 United States

Merck & Co., Inc. (NYSE:MRK) Receives Average Rating of "Moderate Buy" from Analysts

Merck & Co., Inc. (NYSE:MRK) has received an average rating of "Moderate Buy" from twenty-two analysts, with a consensus 1-year price target of $135.50. The company recently reported quarterly revenue of $16.61 billion, exceeding estimates, and declared a quarterly dividend of $0.85 per share. …

MRK main company

Sharemaestro market context Trend signal active 52 weeks +60.7%

08:32 17 Aug 2026

MarketBeat Earnings Main company 🇺🇸 United States

ABN Amro Investment Solutions Has $39.71 Million Stake in Merck & Co., Inc. $MRK

ABN Amro Investment Solutions increased its stake in Merck & Co., Inc. (NYSE:MRK) by 32.3% in the second quarter, bringing its total holdings to 309,009 shares valued at $39.71 million. Other major institutional investors like Vanguard Group Inc., State Street Corp, and Wellington Management …

MRK main company

Sharemaestro market context Trend signal active 52 weeks +60.7%

10:24 16 Aug 2026

MarketBeat Earnings Main company 🇺🇸 United States

Mirae Asset Global Investments Co. Ltd. Buys 245,665 Shares of Merck & Co., Inc. $MRK

Mirae Asset Global Investments Co. Ltd. has increased its stake in Merck & Co., Inc. by 13.7%, now holding over 2 million shares valued at approximately $261.25 million. Institutional investors collectively own 76.07% of MRK, and analysts maintain a "Moderate Buy" rating with a …

MRK main company

Sharemaestro market context Trend signal active 52 weeks +60.7%

09:51 16 Aug 2026

MarketBeat Earnings Main company 🇺🇸 United States

Exchange Traded Concepts LLC Has $14.57 Million Holdings in Merck & Co., Inc. $MRK

Exchange Traded Concepts LLC increased its stake in Merck & Co., Inc. by 28.0% during the second quarter, now holding 113,353 shares valued at $14.57 million. Other institutional investors like Norges Bank and Wellington Management Group LLP also significantly adjusted their positions in MRK. …

MRK main company

Sharemaestro market context Trend signal active 52 weeks +60.7%

16:38 15 Aug 2026

Investing.com Nigeria Earnings Main company 🇺🇸 United States

Merck EVP DeLuca sells $5.9m in stock By Investing.com

Richard R. DeLuca, Executive Vice President and President of Merck Animal Health, sold 45,320 shares of Merck & Co., Inc. (NASDAQ:MRK) common stock for approximately $5.9 million between August 10 and August 12, 2026. Following these transactions, DeLuca directly owns 110,167.07 shares. This news …

MRK main company

Sharemaestro market context Trend signal active 52 weeks +60.7%

11:38 15 Aug 2026

MarketBeat Earnings Main company 🇺🇸 United States

LS Investment Advisors LLC Has $2.88 Million Stock Holdings in Merck & Co., Inc. $MRK

LS Investment Advisors LLC reduced its stake in Merck & Co., Inc. by 28.1% in the second quarter, selling 8,755 shares and retaining 22,418 shares valued at $2.88 million. Despite this, institutional investors collectively own 76.07% of Merck, and analysts maintain a "Moderate Buy" …

MRK main company

Sharemaestro market context Trend signal active 52 weeks +60.7%

11:12 15 Aug 2026

MarketBeat Earnings Main company 🇺🇸 United States

Novem Group Has $7.20 Million Position in Merck & Co., Inc. $MRK

Novem Group significantly increased its stake in Merck & Co., Inc. by 16.1% in the second quarter, bringing its total holdings to 56,016 shares valued at approximately $7.20 million. This move makes Merck Novem Group's 25th largest position. Merck reported strong quarterly revenue and …

MRK main company

Sharemaestro market context Trend signal active 52 weeks +60.7%